| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 1g | 电议 |
Cell lines | Prefrontal cortical (PFC) neurons, Rats hepatocytes |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.1-10 μM for 16-72 h; or 20 - 80 μM for 48 h |
Applications | Clozapine induced initial pERK1-specific blockade and subsequent activation of the ERK response in prefrontal cortical (PFC) neurons in vitro [1]. Moreover, Clozapine (20-80 μM) concentration-dependently induced hepatotoxicity [2]. |
Animal models | C57BL/6 mouse model, Male Sprague-Dawley (SD) rats model |
Dosage form | 1, 2.5 mg/kg; intraperitoneal administration, for 15 h, 24 h; or 25 mg/kg, oral administration, for 7 days |
Applications | Clozapine induced ERK1/2 cell signaling activation via the EGF receptor in mouse prefrontal cortex [1]. Moreover, Clozapine treatment led to marked accumulation of triglyceride and increase in gglutamyl transpeptidase (g-GT) activity, liver weight, and serum AST in rats [2]. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
| 产品描述 | Clozapine (HF 1854) is an antipsychotic used to treat schizophrenia. Clozapine is a potent antagonist of dopamine and a number of other receptors, with a Ki of 9.5 nM for M1 receptor[1][2][3]. Clozapine is also a potent and selective agonist at the muscarinic M4 receptor (EC50=11 nM)[4]. Clozapine shows the unique property of having antipsychotic action but no Parkinson-like motor side effects. The chemical structure of clozapine facilitates a relatively rapid dissociation from D2 receptors. After short-term occupation of D2 receptors, peak neural activity raises synaptic dopamine, which then displaces clozapine. While clozapine also occupies other types of receptors, they may not have a significant role in preventing parkinsonism. Clozapine is very potent at D2 receptor with a Ki of 75 nM. Clozapine is also potent at the α2-adrenoceptor with a Ki value of 51 nM[1]. Clozapine causes paradoxical downregulation of 5-HT2A receptors. Clozapine also binds to 5-HT6 and 5-HT7 receptors with high affnity[2]. Head-twitch response is decreased and [3H]ketanserin binding is downregulated in 1, 7, and 14 days after chronic clozapine. 5-HT2A mRNA is reduced 1 day after chronic clozapine. Induction of c-fos, but not egr-1 and egr-2, is rescued 7 days after chronicclozapine[3]. References: |
m.cnreagent.com